Skip to main content
Top
Published in: Supportive Care in Cancer 9/2012

01-09-2012 | Original Article

Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone

Authors: Christoph Ostgathe, Raymond Voltz, Annika Van Aaaken, Carsten Klein, Rainer Sabatowski, Friedemann Nauck, Jan Gaertner

Published in: Supportive Care in Cancer | Issue 9/2012

Login to get access

Abstract

Introduction

An algorithm to convert from any other opioid to oral levo-methadone was developed in Germany, the German model of levo-methadone conversion (GMLC). According to this GMLC, the pre-existing opioid is stopped, then titration of oral levo-methadone is initiated with a starting dose of 5 mg orally q 4 h (plus prn q 1 h). If necessary, levo-methadone dose is increased (pain) or decreased (side effects) by 30% q 4 h (plus prn q 1 h). After 72 h, the achieved single dose is maintained, but the dosing interval increases twofold to q 8 h (plus prn q 3 h). The aim of this study was to obtain information about the practicability, safety, and efficacy of the GMLC in clinical routine.

Methods

A retrospective, systematic chart review of levo-methadone conversions for the treatment of pain in inpatient palliative care was performed.

Results

Fifty-two patients were analyzed. The dosing interval was increased correctly after 72 h as demanded by the GMLC in 60% of patients. In 85% of the patients, opioid medication with levo-methadone could be maintained until the end of the inpatient stay. In three patients (6%), levo-methadone administration had to be stopped due to side effects. No serious adverse events could be detected during opioid rotation. Pain intensity was reduced significantly (p < 0.001) after conversion concerning mean (NRS 0.9; range 0–4) and maximum pain over the day (NRS 3.9; range 0–10).

Conclusion

The presented study indicates that the GMLC provides a practical and reasonably safe approach to perform opioid rotation to levo-methadone in a palliative care setting.
Literature
1.
go back to reference Ansermot N, Albayrak O, Schlapfer J, Crettol S, Croquette-Krokar M, Bourquin M, Deglon JJ, Faouzi M, Scherbaum N, Eap CB (2010) Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med 170:529–536PubMedCrossRef Ansermot N, Albayrak O, Schlapfer J, Crettol S, Croquette-Krokar M, Bourquin M, Deglon JJ, Faouzi M, Scherbaum N, Eap CB (2010) Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med 170:529–536PubMedCrossRef
2.
go back to reference Bausewein C, Remi C, Twycross R, Wilcock A (2005) Arzneimitteltherapie in der Palliativmedizin. Urban & Fischer Verlag, München Bausewein C, Remi C, Twycross R, Wilcock A (2005) Arzneimitteltherapie in der Palliativmedizin. Urban & Fischer Verlag, München
3.
go back to reference Benitez-Rosario MA, Salinas-Martin A, Aguirre-Jaime A, Perez-Mendez L, Feria M (2009) Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 37:1061–1068PubMedCrossRef Benitez-Rosario MA, Salinas-Martin A, Aguirre-Jaime A, Perez-Mendez L, Feria M (2009) Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 37:1061–1068PubMedCrossRef
4.
go back to reference Bruera E, Pereira J, Watanabe S (1996) Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRef Bruera E, Pereira J, Watanabe S (1996) Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRef
5.
go back to reference Bruera E, Sweeney C (2002) Methadone use in cancer patients with pain: a review. J Palliat Med 5:127–138PubMedCrossRef Bruera E, Sweeney C (2002) Methadone use in cancer patients with pain: a review. J Palliat Med 5:127–138PubMedCrossRef
6.
go back to reference Davis MP, Walsh D (2001) Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9:73–83PubMedCrossRef Davis MP, Walsh D (2001) Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9:73–83PubMedCrossRef
8.
go back to reference Gaertner J, Voltz R, Ostgathe C (2008) Methadone: a closer look at the controversy. J Pain Symptom Manage 36:e4–e7PubMedCrossRef Gaertner J, Voltz R, Ostgathe C (2008) Methadone: a closer look at the controversy. J Pain Symptom Manage 36:e4–e7PubMedCrossRef
9.
go back to reference Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F (2005) Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 19:477–484PubMedCrossRef Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F (2005) Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 19:477–484PubMedCrossRef
10.
go back to reference Krantz MJ, Mehler PS (2006) QTc prolongation: methadone's efficacy-safety paradox. Lancet 368:556–557PubMedCrossRef Krantz MJ, Mehler PS (2006) QTc prolongation: methadone's efficacy-safety paradox. Lancet 368:556–557PubMedCrossRef
11.
go back to reference Lin C, Somberg T, Molnar J, Somberg J (2009) The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiol 113:59–65CrossRef Lin C, Somberg T, Molnar J, Somberg J (2009) The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiol 113:59–65CrossRef
12.
go back to reference Mancini I, Lossignol DA, Body JJ (2000) Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 12:308–313PubMedCrossRef Mancini I, Lossignol DA, Body JJ (2000) Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 12:308–313PubMedCrossRef
13.
go back to reference Morley JS, Makin MK (1998) The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews 5:51–58CrossRef Morley JS, Makin MK (1998) The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews 5:51–58CrossRef
14.
go back to reference Nauck F, Ostgathe C, Dickerson ED (2001) A German model for methadone conversion. Am J Hosp Palliat Care 18:200–202PubMedCrossRef Nauck F, Ostgathe C, Dickerson ED (2001) A German model for methadone conversion. Am J Hosp Palliat Care 18:200–202PubMedCrossRef
15.
go back to reference Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef
16.
go back to reference Ostgathe C, Gaertner J, Nauck F, Voltz R (2008) High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction. J Pain Symptom Manage 35:229–231PubMedCrossRef Ostgathe C, Gaertner J, Nauck F, Voltz R (2008) High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction. J Pain Symptom Manage 35:229–231PubMedCrossRef
17.
go back to reference Ostgathe C, Radbruch L, Nauck F, Elsner F (2007) Cancer pain management. Zeitschrift für Palliativmedizin 8:13–30CrossRef Ostgathe C, Radbruch L, Nauck F, Elsner F (2007) Cancer pain management. Zeitschrift für Palliativmedizin 8:13–30CrossRef
18.
go back to reference Pollock AB, Tegeler ML, Morgan V, Baumrucker SJ (2011) Morphine to methadone conversion: an interpretation of published data. Am J Hosp Palliat Care 28:135–140PubMedCrossRef Pollock AB, Tegeler ML, Morgan V, Baumrucker SJ (2011) Morphine to methadone conversion: an interpretation of published data. Am J Hosp Palliat Care 28:135–140PubMedCrossRef
19.
go back to reference Ripamonti C, Dickerson ED (2001) Strategies for the treatment of cancer pain in the new millennium. Drugs 61:955–977PubMedCrossRef Ripamonti C, Dickerson ED (2001) Strategies for the treatment of cancer pain in the new millennium. Drugs 61:955–977PubMedCrossRef
20.
go back to reference Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216–3221PubMed Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216–3221PubMed
21.
go back to reference Ripamonti C, Groff L, Brunelli C, Polastri D, Stravakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? J Clin Oncol 16(10):3216–3221PubMed Ripamonti C, Groff L, Brunelli C, Polastri D, Stravakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? J Clin Oncol 16(10):3216–3221PubMed
22.
go back to reference Tse DM, Sham MM, Ng DK, Ma HM (2003) An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med 17:206–211PubMedCrossRef Tse DM, Sham MM, Ng DK, Ma HM (2003) An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med 17:206–211PubMedCrossRef
23.
go back to reference Watanabe S (2001) Methadone: the renaissance. J Palliat Care 17:117–120PubMed Watanabe S (2001) Methadone: the renaissance. J Palliat Care 17:117–120PubMed
24.
go back to reference Weschules DJ, Bain KT (2008) A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9:595–612PubMedCrossRef Weschules DJ, Bain KT (2008) A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9:595–612PubMedCrossRef
Metadata
Title
Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone
Authors
Christoph Ostgathe
Raymond Voltz
Annika Van Aaaken
Carsten Klein
Rainer Sabatowski
Friedemann Nauck
Jan Gaertner
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 9/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1320-8

Other articles of this Issue 9/2012

Supportive Care in Cancer 9/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine